化疗诱导坏死对高危局限性骨肉瘤生存的影响
该研究纳入1997至2016年间232例≤40岁、初诊无临床可检测转移并接受术前MAP化疗及手术的高级别局限性骨肉瘤患者。多因素Cox模型显示化疗诱导坏死与无事件生存(EFS)和总生存(OS)显著相关,坏死与5年EFS、OS呈正相关;EFS和OS的最佳截断值分别为85%和72%,低于常用的90%。
要点
- 化疗诱导坏死与EFS、OS显著相关,5年OS为74%(95%CI 67至79)。
- 坏死与5年EFS正相关(r=0.91),与5年OS正相关(r=0.85)。
- EFS与OS最佳截断值分别为85%和72%,低于常用90%。
核心结论
- 切除标本中化疗诱导坏死与高级别局限性骨肉瘤患者MAP化疗后的EFS和OS呈正相关。
- 本分析中EFS与OS的最佳截断值低于常用的90%,提示需通过更大规模国际协作研究重新评估最佳截断值。
研究设计与样本
- 回顾性纳入1997至2016年625例≤40岁原发高级别骨肉瘤患者中的232例,均初诊无临床可检测转移并接受术前高剂量甲氨蝶呤、阿霉素和顺铂(MAP)化疗及手术。
- 采用Cox模型和Pearson相关系数评估坏死与EFS、OS的关联,并应用时间依赖ROC分析确定最佳截断值。
主要发现
- 5年OS为74%(95%CI 67至79)。
- 化疗诱导坏死中位数为85%(IQR 50%至97%)。
- 多因素Cox模型中坏死与EFS显著相关(HR=0.99,95%CI 0.98至0.99;p<0.001),与OS显著相关(HR=0.98,95%CI 0.97至0.99;p<0.001)。
- 坏死与5年EFS正相关(r=0.91;p<0.001),与5年OS正相关(r=0.85;p<0.001)。
关键数值与推荐
- 5年EFS的最佳化疗诱导坏死截断值为85%。
- 5年OS的最佳化疗诱导坏死截断值为72%。
临床怎么用
- 对接受术前MAP化疗的高级别局限性骨肉瘤患者,可依据切除标本坏死程度评估EFS和OS风险。
- 本研究中EFS与OS最佳截断值低于常用90%,提示临床解读坏死阈值时需谨慎并期待更大规模研究验证。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To assess the correlation between the histological response to preoperative chemotherapy and event-free survival (EFS) or overall survival (OS) in patients with high-grade localized osteosarcoma. METHODS: Out of 625 patients aged ≤ 40 years treated for primary high-grade osteosarcoma between 1997 and 2016, 232 patients without clinically detectable metastases at the time of diagnosis and treated with preoperative high-dose methotrexate, adriamycin and cisplatin (MAP) chemotherapy and surgery were included. Associations of chemotherapy-induced necrosis in the resected specimen and EFS or OS were assessed using Cox model and the Pearson's correlation coefficients (r). Time-dependent receiver operating characteristic analysis was applied to determine the optimal cut-off value of chemotherapy-induced necrosis for EFS and OS. RESULTS: OS was 74% (95% confidence interval (CI) 67 to 79) at five years. Median chemotherapy-induced necrosis was 85% (interquartile range (IQR) 50% to 97%). In multivariate Cox model, chemotherapy-induced necrosis was significantly associated with EFS and OS (hazard ratio (HR) = 0.99 (95% CI 0.98 to 0.99); p < 0.001 and HR = 0.98 (95% CI 0.97 to 0.99); p < 0.001, respectively). Positive correlation was observed between chemotherapy-induced necrosis and five-year EFS and five-year OS (r = 0.91; p < 0.001, and r = 0.85; p < 0.001, respectively). The optimal cut-off value of chemotherapy-induced necrosis for five-year EFS and five-year OS was 85% and 72%, respectively. CONCLUSION: Chemotherapy-induced necrosis in the resected specimen showed positive correlation with EFS and OS in patients with high-grade localized osteosarcoma after MAP chemotherapy. In our analysis, optimal cut-off values of MAP chemotherapy-induced necrosis in EFS and OS were lower than the commonly used 90%, suggesting the need for re-evaluation of the optimal cut-off value through larger, international collaborative research. Cite this article: Bone Joint J 2020;102-B(6):795-803.
引用
- Tsuda Y, Tsoi K, Parry MC, et al. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma. Bone Joint J. 2020. PMID: 32475245. doi:10.1302/0301-620X.102B6.BJJ-2019-1307.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。